Kimball Electronics (KE) Q2 2026: Medical Sales Jump 15% as New Indy Facility Drives Vertical Shift
Kimball Electronics’ medical vertical delivered robust double-digit growth, offsetting automotive and industrial softness while the company raised full-year guidance on the back of its new Indianapolis facility. Strategic bets on medical contract manufacturing and vertical integration are reshaping the business model, but near-term margin drag and end-market volatility remain key watchpoints. Investors should monitor execution on new medical programs and the pace of automotive stabilization, as the company leans into higher-value, precision manufacturing solutions.
Summary
- Medical Expansion Accelerates: New Indianapolis facility and medical wins reposition the business mix.
- Automotive Headwinds Fade: North America and China remain soft, but Europe and new programs offer stabilization.
- Strategic Rebrand Signals Shift: “Kimball Solutions” and vertical integration mark a long-term pivot beyond legacy EMS.
Business Overview
Kimball Electronics is a global contract manufacturer specializing in medical, automotive, and industrial electronics, generating revenue through design, engineering, and high-level assembly services. The business is organized into three primary verticals: medical (28% of sales), automotive (48%), and industrial (24%), with operations spanning North America, Europe, and Asia. The company is increasingly focused on higher-value medical contract manufacturing and integrated solutions, as evidenced by recent facility investments and a pending rebrand to “Kimball Solutions.”
Performance Analysis
Second quarter results showcased a pronounced divergence between verticals. Medical revenue surged 15% year over year, marking its fourth consecutive quarter of growth and now comprising over a quarter of total sales. This was fueled by gains in Poland and Thailand, while North America was flat. In contrast, automotive sales fell 13% on program roll-offs and tariff pressures in North America, with China also weak, though European growth in steering and braking programs partially offset declines. Industrial sales slipped 5%, largely due to North American HVAC demand softness, with Europe rebounding on smart meter programs.
Gross margin improved by 160 basis points to 8.2%, driven by favorable mix, restructuring, and the closure of the Tampa facility. Operating income margin rose to 4.5% despite the top-line decline, reflecting disciplined cost management and early benefits from restructuring. Cash flow from operations remained positive for the eighth straight quarter, though cash conversion days ticked up sequentially, reflecting working capital pressures in automotive and industrial. Capital expenditures were concentrated on the new Indianapolis medical facility, which is expected to be a long-term growth engine but will create near-term margin drag as it ramps.
- Medical Outperformance: Double-digit growth and new facility investments are transforming the company’s revenue mix and margin profile.
- Automotive Program Transition: End of the Renosa braking program and tariff impacts weighed on North America, but European programs are ramping.
- Margin Management: Restructuring, mix shift, and facility closures supported margin expansion despite revenue declines and ramp costs.
Share repurchases continued, with $4.3 million deployed in Q2, and the balance sheet remains healthy, with liquidity of $363 million. The company raised its full-year guidance for both sales and operating margin, anchored by confidence in medical and European automotive programs.
Executive Commentary
"Our focus as a medical CMO continues to gain momentum as we leverage our unique capabilities in the industry. We expect top-line growth in medical to outpace our other two verticals as we balance our portfolio across the markets we serve."
Rick, Chief Executive Officer
"Expense will be higher in FY26 as we make strategic investments in business transformation, IT solutions, and business development for the future. We have worked hard to balance the needs of the business against the backdrop of declining sales."
Jana Kroon, Chief Financial Officer
Strategic Positioning
1. Medical Vertical Ascendancy
The company’s deliberate pivot into medical contract manufacturing is reshaping its growth trajectory. The Indianapolis facility adds significant capacity, targeting high-precision, long-life products such as single-use surgical instruments and drug delivery devices. Medical is now the fastest-growing and most diversified vertical, benefiting from demographic tailwinds and regulatory complexity that favor established players.
2. Automotive Resilience Amid Transition
Automotive remains the largest segment but faces structural churn. While North America and China are pressured by program roll-offs and tariffs, European programs in steering and braking are ramping. Emerging opportunities in electronic power packs (EPP) and second steering systems position Kimball for the next wave of automotive electronics, especially as ADAS (advanced driver-assistance systems) content grows.
3. Industrial Stabilization Efforts
Industrial is heavily North America-centric and exposed to cyclical HVAC demand. While this vertical declined in Q2, European smart meter growth provided a partial offset, and management continues to prioritize cost alignment and selective growth opportunities.
4. Rebranding and Solution Expansion
The upcoming rebrand to “Kimball Solutions” signals a strategic shift beyond traditional EMS (Electronics Manufacturing Services). The company is broadening its offering to encompass design, supply chain, and high-level assemblies, seeking to deepen customer relationships and enable vertical integration, particularly in medical.
5. Disciplined Capital Deployment
Share repurchases and targeted capex reflect a balanced approach to capital allocation, with a focus on supporting growth in medical while maintaining liquidity and debt discipline.
Key Considerations
This quarter marks a pivotal inflection as Kimball Electronics transitions from a legacy EMS model to a diversified, solutions-oriented manufacturing partner. The company is betting on medical and high-value automotive programs to offset legacy volatility, but execution risks remain as new facilities ramp and cost structures evolve.
Key Considerations:
- Medical Facility Ramp Dynamics: The Indianapolis plant offers significant growth potential but will pressure margins for several quarters as it ramps and transitions workstreams.
- Automotive Program Mix Shift: European wins and new EPP programs are offsetting North American declines, but overall segment growth will be muted until new programs scale.
- Cash Conversion Focus: Elevated cash conversion days reflect working capital drag, with management signaling a renewed focus on inventory and receivables discipline.
- Strategic M&A Optionality: Management is actively evaluating acquisitions in attractive medical sub-verticals like in vitro diagnostics and cardiology to accelerate diversification.
- Rebranding Execution: The phased rollout of the Kimball Solutions identity will require operational and cultural alignment to deliver on the expanded value proposition.
Risks
End-market volatility in North America automotive and industrial remains a key risk, particularly as tariff impacts and macroeconomic uncertainty persist. The medical ramp, while promising, carries execution and customer concentration risk as new programs scale. Near-term margin drag from facility investments and elevated tax rates could pressure profitability, and competitive intensity in contract manufacturing remains high, especially as the company seeks larger, higher-margin programs.
Forward Outlook
For Q3, Kimball Electronics guided to:
- Automotive revenues stabilizing, with the impact of the Renosa program roll-off fully annualized and European programs ramping.
- Medical growth to continue, though Q3 comps will be affected by a prior-year inventory sale; management will provide adjusted growth metrics.
For full-year 2026, management raised guidance:
- Net sales of $1.4 to $1.46 billion, up from $1.35 to $1.45 billion previously.
- Adjusted operating income margin of 4.2% to 4.5%, versus prior range of 4.0% to 4.25%.
Management emphasized several factors influencing the outlook:
- Continued strength in medical and European automotive verticals, with new program ramps.
- Ongoing cost discipline and restructuring to offset margin drag from new facility investments.
Takeaways
Kimball Electronics is executing a strategic pivot toward higher-value medical and automotive programs, supported by new capacity and a broadened solutions portfolio. While medical is now the principal growth engine, short-term margin and working capital pressures must be managed as new facilities come online and legacy programs sunset.
- Medical Mix Shift: The Indianapolis facility and medical program wins are redefining the company’s growth profile and margin potential, but require flawless execution to realize full value.
- Automotive Reset: With North American headwinds easing and European programs scaling, automotive is stabilizing, yet remains exposed to macro and regulatory risk.
- Execution Watchpoints: Investors should closely monitor margin recovery, cash cycle improvement, and the pace of medical and industrial program ramps over the next several quarters.
Conclusion
Kimball Electronics is at a strategic crossroads, leveraging medical vertical momentum and facility investments to drive long-term value, while managing near-term operational and market challenges. The company’s focus on diversification, customer intimacy, and solution expansion positions it for sustainable growth, but execution risk and end-market volatility warrant ongoing scrutiny.
Industry Read-Through
Kimball Electronics’ pivot toward medical contract manufacturing and vertical integration reflects broader industry trends, as EMS providers seek to move up the value chain and capture higher-margin, complex programs. The company’s ability to scale new facilities and win larger, longer-cycle medical business highlights rising barriers to entry in regulated markets. Automotive program churn and tariff sensitivity are cautionary signals for peers with North American exposure, while the emphasis on European growth and ADAS content points to secular tailwinds for suppliers aligned with next-generation vehicle architectures. The rebranding to “Solutions” mirrors a sector-wide shift toward end-to-end offerings, underscoring the need for operational agility and customer-centricity in a consolidating industry.